Tradestie Institutional Equity Comparison Engine

SBIO vs FBT โ€” Head-to-Head Terminal

6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.

Market Close: 2026-11-16 Buy Verdict Report Ask Alpha

Pillar 1 Executive Scorecard & Category Winner Tally

FBT Overall Edge

FBT Captures Institutional Edge (2โ€“0 Pillars ยท 3โ€“0 Matrix Metrics)

Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to First Trust NYSE Arca Biotechnology Index Fund (FBT) driven by superior Momentum & Technical, Options & Structure. Fundamentally, SBIO trades at N/M Forward P/E with N/A operating margin (N/A YoY revenue) versus FBT at N/M Forward P/E and N/A operating margin (N/A YoY). In options structure, SBIO sits in UNCLASSIFIED (6th %ile IV; Dealer Gamma Walls on Pro) against FBT sits in UNCLASSIFIED (4th %ile IV; Dealer Gamma Walls on Pro).

Valuation Winner Tie
SBIO N/M vs FBT N/M Fwd P/E
Growth & Margin Winner Tie
Op Margin N/A vs N/A ยท YoY N/A vs N/A
Momentum & Technical Winner FBT
1Y +19.0% vs +33.7% ยท 52W Pos 35% vs 83%
Options & Structure Winner FBT
UNCLASSIFIED (6th %ile IV) vs UNCLASSIFIED (4th %ile IV)
SBIO NYSE Arca
ALPS Medical Breakthroughs ETF
Institutional Equity
$53.87
-3.17% 1D
Market Cap N/A
1M Return +7.48%
1Y Return +19.0%
Forward P/E N/M
Unified AI Score
46.4 / 100 HOLD
Tech 48.0 Fund 51.0 Flow 50.0 Mom 60.0
FBT NYSE Arca
First Trust NYSE Arca Biotechnology Index Fund
Institutional Equity
$266.97
-1.5% 1D
Market Cap N/A
1M Return +1.28%
1Y Return +33.69%
Forward P/E N/M
Unified AI Score
53.1 / 100 HOLD
Tech 45.0 Fund 45.0 Flow 50.0 Mom 41.1

Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)

1Y Indexed Return: SBIO +19.0% FBT +33.69% Spread: +14.69 pp (FBT Lead)

Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant Revenue ($B) & Operating Margin (%)
SBIO TTM Op. Margin: N/A FBT TTM Op. Margin: N/A
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on SBIO vs FBT. Trailing 12-month operating profitability (SBIO N/A vs FBT N/A) and valuation multiples (SBIO N/M vs FBT N/M Forward P/E) are benchmarked directly in Pillar 4 below.

Pillar 4 Head-to-Head Fundamental & Valuation Matrix

Matrix Tally: SBIO (0) vs FBT (3)
Institutional Metric SBIO FBT Criterion Row Winner
Market Capitalization Scale N/A N/A Larger Scale Tie
Trailing P/E Ratio Valuation N/M N/M Lower Multiple Tie
Forward P/E Ratio Valuation N/M N/M Lower Multiple Tie
Revenue Growth (YoY) Growth N/A N/A Higher Growth Tie
Operating Margin (TTM) Profitability N/A N/A Higher Margin Tie
Net Profit Margin Profitability N/A N/A Higher Margin Tie
Return on Equity (ROE) Capital Efficiency N/A N/A Higher ROE Tie
52-Week Range Position Momentum 35% ($45โ€“$71) 83% ($189โ€“$283) Stronger Trend FBT
Beta / 30D Volatility Risk Regime 1.21ฮฒ ยท 44% Vol 0.79ฮฒ ยท 27% Vol Lower Realized Risk FBT
Unified Institutional Score Composite Signal 46.4 / 100 (HOLD) 53.1 / 100 (HOLD) Higher Composite FBT

Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor

Full SBIO vs FBT Buy Guide
SBIO UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 6th %ile
IV Regime Compressed (<25th %ile)
Live SBIO Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →
FBT UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 4th %ile
IV Regime Compressed (<25th %ile)
Live FBT Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →

Pillar 6 90-Day Technical & R&D Innovation Disclosures

Corporate R&D & Foundry Tracker
Neither SBIO nor FBT registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.